Cited by 44Parkinson's Disease Mechanisms and TreatmentsNuclear Receptors and SignalingNeurological Disorders and Treatments

Enhanced accumulation of reduced glutathione by Scopoletin improves survivability of dopaminergic neurons in Parkinson’s model

Open access
Pradhan, Priyadarshika, Majhi, Olivia, Biswas, Abhijit, Joshi, Vinod Kumar, Sinha, Devanjan·2020·Cell Death & Disease

Abstract

Parkinson’s disease (PD) is a neuromotor disorder, primarily manifested by motor anomalies due to progressive loss of dopaminergic neurons. Although alterations in genetic factors have been linked with its etiology, exponential accumulation of environmental entities such as reactive oxygen species (ROS) initiate a cyclic chain reaction resulting in accumulation of cellular inclusions, dysfunctional mitochondria, and overwhelming of antioxidant machinery, thus accelerating disease pathogenesis. Involvement of oxidative stress in PD is further substantiated through ROS induced Parkinsonian models and elevated oxidative markers in clinical PD samples; thereby, making modulation of neuronal oxidative load as one of the major approaches in management of PD. Here we have found a potent antioxidant moiety Scopoletin (Sp), a common derivative in most of the nootropic herbs, with robust neuroprotective ability. Sp increased cellular resistance to ROS through efficient recycling of GSH to prevent oxidative damage. The Sp treated cells showed higher loads of reduced glutathione making them resistant to perturbation of antioxidant machinery or neurotoxin MPP+. Sp could restore the redox balance, mitochondrial function, and prevented oxidative damage, leading to recovery of dopaminergic neural networks and motion abilities in Drosophila genetic model of PD. Our data also suggest that Sp, in combination increases the therapeutic potency of L-DOPA by mitigating its chronic toxicity. Together, we highlight the possible ability of Sp in preventing oxidative stress mediated loss of dopaminergic neurons and at the same time enhance the efficacy of dopamine recharging regimens.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41419-020-02942-8

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Both in vitro and in vivo experiments confirmed that restoring levels of glutathione in PD patients represents a promising strategy to slow down progression of disease.

    “Both in vitro and in vivo experiments confirmed that restoring levels of glutathione in PD patients represents a promising strategy to slow down the progression of the disease (Pradhan et al. 2020).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Pradhan, P., Majhi, O., Biswas, A., Joshi, V. K., & Sinha, D.
Affiliations
  • Banaras Hindu University (IN)
  • Institute of Medical Sciences (IN)
Corresponding author
Sinha, Devanjan
Venue
Cell Death & Disease
Published
2020-09-10
Volume
11
Issue
9
Pages
739-739
ISSN
2041-4889 (ISSN-L)
OpenAlex
W3083817188
Cited by
44
References
60
Citations by year
2026: 3 · 2025: 4 · 2024: 8 · 2023: 10 · 2022: 15 · 2021: 4
FWCI
3.14
Type
journal article
Language
en
Open access
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Indian National Science Academy (INSA/SP/YSP/152/2018/232)
Topics
  • Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nuclear Receptors and Signaling
  • Life Sciences › Neuroscience › Neurology › Neurological Disorders and Treatments
Keywords
scopoletin, Parkinson's disease, dopaminergic neurons, reduced glutathione, oxidative stress, reactive oxygen species, neuroprotection, MPP+ neurotoxicity, mitochondrial function, redox homeostasis
MeSH terms
Animals, Dopamine, Drosophila, Glutathione, Humans, Parkinson Disease, Scopoletin, Survival Analysis, Oxidative Stress

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review